Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TMIFRY8XAG (4-oxo-1,4-dihydroquinoline-2-carboxylic acid) is a derivative of Zerumbone with potential anti-tumor effects towards HeLa cancer cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 55.00 | |
10 mg | In stock | $ 79.00 | |
25 mg | In stock | $ 142.00 | |
50 mg | In stock | $ 202.00 | |
100 mg | In stock | $ 303.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 66.00 |
Description | TMIFRY8XAG (4-oxo-1,4-dihydroquinoline-2-carboxylic acid) is a derivative of Zerumbone with potential anti-tumor effects towards HeLa cancer cells. |
Synonyms | 1,1'-(4-CHLOROBUTYLIDENE)BIS(4-FLUOROBENZENE), 4-oxo-1,4-dihydroquinoline-2-carboxylic acid |
Molecular Weight | 280.74 |
Formula | C16H15ClF2 |
CAS No. | 3312-04-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 9 mg/mL (32.06 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TMIFRY8XAG 3312-04-7 Others 1,1'-(4-CHLOROBUTYLIDENE)BIS(4-FLUOROBENZENE) 4-oxo-1,4-dihydroquinoline-2-carboxylic acid TMIFRY-8XAG inhibitor inhibit